Theratechnologies (THTX) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Theratechnologies in May 2026.
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
Stock Performance Snapshot
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring THTX
The Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.